90K (Mac-2 BP) and galectins in tumor progression and metastasis
- PMID: 14758079
- DOI: 10.1023/B:GLYC.0000014085.00706.d4
90K (Mac-2 BP) and galectins in tumor progression and metastasis
Abstract
Galectins and their ligands have been implicated in cell transformation and cancer metastasis, and found to have prognostic value. Mac-2 BP, also known as 90K, is a highly glycosylated, secreted protein extensively studied in human cancer, which binds galectin-1, galectin-3 and galectin-7. High expression levels of 90K are associated with a shorter survival, the occurrence of metastasis or a reduced response to chemotherapy in patients with different types of malignancy. The mechanisms underlying the prognostic significance of 90K and galectins in cancer are far from being understood, although they may be related to the ability of these proteins to interact and, to some extent, modulate cell-cell and cell-matrix adhesion and apoptosis. The resulting scenario is even more complex, as data have been presented that all these proteins might be associated with either a positive or a negative outcome of the patients. It is hypothesised that different galectins and galectin ligands with overlapping or opposite functions, expressed in different tumors during the different steps of the metastatic cascade might play a crucial role in tumor progression.
Similar articles
-
Circulating Galectin-1 and 90K/Mac-2BP Correlated with the Tumor Stages of Patients with Colorectal Cancer.Biomed Res Int. 2015;2015:306964. doi: 10.1155/2015/306964. Epub 2015 Sep 13. Biomed Res Int. 2015. PMID: 26448934 Free PMC article. Clinical Trial.
-
Glycoprotein 90K/MAC-2BP interacts with galectin-1 and mediates galectin-1-induced cell aggregation.Int J Cancer. 2001 Jan 15;91(2):167-72. doi: 10.1002/1097-0215(200002)9999:9999<::aid-ijc1022>3.3.co;2-q. Int J Cancer. 2001. PMID: 11146440
-
Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients.Cancer Res. 2002 May 1;62(9):2535-9. Cancer Res. 2002. PMID: 11980646
-
Intracellular galectins in cancer cells: potential new targets for therapy (Review).Int J Oncol. 2014 Apr;44(4):1001-14. doi: 10.3892/ijo.2014.2267. Epub 2014 Jan 21. Int J Oncol. 2014. PMID: 24452506 Review.
-
Vascular galectins: regulators of tumor progression and targets for cancer therapy.Cytokine Growth Factor Rev. 2013 Dec;24(6):547-58. doi: 10.1016/j.cytogfr.2013.07.003. Epub 2013 Aug 12. Cytokine Growth Factor Rev. 2013. PMID: 23942184 Review.
Cited by
-
Introduction to galectins.Glycoconj J. 2002;19(7-9):433-40. doi: 10.1023/B:GLYC.0000014072.34840.04. Glycoconj J. 2002. PMID: 14758066 Review.
-
Tumor biomarker glycoproteins in the seminal plasma of healthy human males are endogenous ligands for DC-SIGN.Mol Cell Proteomics. 2012 Jan;11(1):M111.008730. doi: 10.1074/mcp.M111.008730. Epub 2011 Oct 10. Mol Cell Proteomics. 2012. PMID: 21986992 Free PMC article.
-
Proteomic analysis of cerebrospinal fluid in pediatric acute lymphoblastic leukemia patients: a pilot study.Onco Targets Ther. 2019 May 17;12:3859-3868. doi: 10.2147/OTT.S193616. eCollection 2019. Onco Targets Ther. 2019. PMID: 31190885 Free PMC article.
-
Broad and thematic remodeling of the surfaceome and glycoproteome on isogenic cells transformed with driving proliferative oncogenes.Proc Natl Acad Sci U S A. 2020 Apr 7;117(14):7764-7775. doi: 10.1073/pnas.1917947117. Epub 2020 Mar 23. Proc Natl Acad Sci U S A. 2020. PMID: 32205440 Free PMC article.
-
Lectin galactoside-binding soluble 3 binding protein (LGALS3BP) is a tumor-associated immunomodulatory ligand for CD33-related Siglecs.J Biol Chem. 2014 Nov 28;289(48):33481-91. doi: 10.1074/jbc.M114.593129. Epub 2014 Oct 15. J Biol Chem. 2014. PMID: 25320078 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous